Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Bioavailability Enhancement Technologies and Services Market, 2030 - A Detailed Analysis of 6,000+ Patents Related to Bioavailability Enhancement Technologies


DUBLIN, June 21, 2018 /PRNewswire/ --

The "Bioavailability Enhancement Technologies and Services Market, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Bioavailability Enhancement Technologies and Services Market, 2018-2030' report provides a comprehensive study on the current scenario of technologies and contract services related to bioavailability enhancement. The study features an elaborate discussion on the novel approaches adopted by different players offering solutions for altering the bioavailability of various drugs.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as likely number of candidates in BCS II and IV, likely adoption rates of bioavailability enhancement approaches, expected trend in outsourcing and likely pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.

To account for the uncertainties associated with the expected future demand and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to increase further.

It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability (via the 505(b)(2) pathway), the demand for novel bioavailability enhancement methods has grown significantly.

To cater to this increasing demand, several contract manufacturers and technology providers have emerged in this domain. With more than 150 companies offering technologies / services for bioavailability enhancement, the market is highly fragmented; having said that, several mergers / acquisitions have also taken place as stakeholders strive to broaden their respective service portfolios. A number of players have developed novel, state-of-the art technologies to maintain a competitive edge in this rapidly emerging market.

As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace. In fact, since 2010, more than 4,000 articles, evaluating various bioavailability enhancement technologies have been published across several reputed journals. In addition, more than 6,000 patents have been filed post 2010, providing a significant scientific push to the development of novel approaches.

Amongst other elements, the report features:

Key Topics Covered:

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1 An Overview of Drug Bioavailability
3.2 Need of Bioavailability Enhancement
3.3 Evolution of Bioavailability Enhancement Technologies
3.4 Studies for Assessment of Bioavailability
3.5. Factors Affecting Bioavailability
3.6. Bioavailability Enhancement Technologies
3.7. Trends in Bioavailability Enhancement

4. Market Overview
4.1. Chapter Overview
4.2. Bioavailability Enhancement: List of Service Providers

5. Company Profiles
5.1. Chapter Overview
5.2. Lonza
5.3. Catalent
5.4. Ascendia Pharmaceuticals
5.5. Particle Sciences (Acquired by Lubrizol)
5.6. Juniper Pharma Services
5.7. Phosphorex
5.8. Kuecept (Acquired by Aptuit / Evotec)
5.9. Creative Biolabs
5.10. WuXi AppTec

6. Benchmark Analysis
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups

7. Partnerships And Collaborations
7.1. Chapter Overview
7.2. Types of Partnerships
7.3. Bioavailability Enhancement: Analysis of Partnerships

8. Publication Analysis
8.1. Chapter Overview
8.2. Bioavailability Enhancement: Analysis of Publications

9. Patent Analysis
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Bioavailability Enhancement: Analysis of Patents

10. Clinical Trials Analysis
10.1. Chapter Overview
10.2. Guidelines to Conduct Bioavailability Studies
10.3. Clinical Trials Analysis

11. Demand Analysis
11.1. Chapter Overview
11.2. Bioavailability Enhancement Opportunities
11.3. Research Methodology
11.4. Demand Analysis: New Chemical Entities (NCEs)
11.5. Demand Analysis: Generics

12. Market Forecast
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall Bioavailability Enhancement Market, 2018-2030
12.4. Bioavailability Enhancement Market: Distribution by BCS Classification
12.5. Bioavailability Enhancement Market: Distribution by Type of Bioavailability Enhancement Approach
12.6. Bioavailability Enhancement Market: Distribution by Geographical Location

13. Conclusion
13.1. Challenges Associated with Low Solubility and Permeability of Drugs Has Led to Increasing Demand for Bioavailability Enhancement
13.2. The Market is Characterized by The Presence of Several Established Players, As Well As Small and Mid-Sized Companies in Different Geographies
13.3. Size Reduction, Solid Dispersion and Lipid Based Methods are Offered by Several Technology / Service Providers; Players Offering Other Approaches are Also Emerging
13.4. The Field Has Witnessed Increasing Partnership Activity As Multiple Players are Collaborating for Expanding Capabilities
13.5. Ongoing Advances Have Led to Rapid Innovation and Increase in Patent Filling Activity
13.6. The Rising Number of BCS II and BCS IV Drugs and Increasing Adoption of Different Approaches for Enhancement of Drug Bioavailability is Likely to Foster the Long-Term Growth

14. Transcripts Of Public Discussions
14.1. Chapter Overview
14.2. David Vodak, Vice President of Chemistry, Bend Research
14.3. John K Tilloston, Pharmaceutical and Nutritional Technical Business Director, ABITEC
14.4. Kaspar van den Dries, Senior Director Formulation Sciences and Martin Piest, Senior Formulation Scientist, Patheon
14.5. Anonymous, MilliporeSigma Process Solutions
14.6. Brent Moody, Principal Scientist, Science and Technology, Catalent Pharma Solutions
14.7. Anonymous, Sancilio Pharmaceuticals
14.8. Frank Romanski, BASF Pharma Solutions
14.9. Karl Kolter, BASF Pharma Solutions

15. Appendix 1: Tabular Data

16. Appendix 2: List Of Companies

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/zc7k4j/bioavailability?w=5

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



SOURCE Research and Markets


These press releases may also interest you

at 09:26
CNFinance Files Annual Report on Form 20-F for Fiscal Year 2023
CNFinance Holdings Limited ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and...

at 09:15
JTV® Expands Product Line with Luxury Sunglasses and Watches
JTV®, the national jewelry retailer, broadcast network, and e-commerce platform, is excited to announce the highly anticipated addition of luxury sunglasses and watches to its portfolio of stunning jewelry, loose gemstones, and accessories. This...

at 09:15
Renoworks Announces Annual and Record Fourth Quarter 2023 Financial Results and Provides Outlook
Renoworks Software Inc. ("Renoworks" or the "Company), an industry leader in visualization and lead generation technology for the home renovation and new construction sector, announces its financial results for the year ended December 31, 2023. The...

at 09:10
TransAct Technologies to Report First Quarter 2024 Results On May 7, 2024, Host Conference Call and Webcast
TransAct Technologies Incorporated , a global leader in software-driven technology and printing solutions for high-growth markets, announced today that it will release its first quarter 2024 results before the market opens on Tuesday, May 7, 2024,...

at 09:10
CobbleStone Software Dives Deep into the Benefits of AI-Based Contract Management
CobbleStone Software ? a recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrixtm Report? continues to inform professionals of the benefits of implementing an effective, AI-based CLM software within their...

at 09:05
Aspen Technology Introduces New Strategic Planning for Sustainability Pathways Solution
Aspen Technology, Inc. , a global leader in industrial software, today introduced AspenTech Strategic Planning for Sustainability Pathwaystm ? a new and unique integrated modelling and optimization solution that aims to guide companies in carbon...

More news about Science and technology...


News published on and distributed by: